243 related articles for article (PubMed ID: 18544744)
1. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Grady D; Cauley JA; Geiger MJ; Kornitzer M; Mosca L; Collins P; Wenger NK; Song J; Mershon J; Barrett-Connor E;
J Natl Cancer Inst; 2008 Jun; 100(12):854-61. PubMed ID: 18544744
[TBL] [Abstract][Full Text] [Related]
2. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
3. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
4. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
[TBL] [Abstract][Full Text] [Related]
5. Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.
Vogel VG
Clin Interv Aging; 2008; 3(4):601-9. PubMed ID: 19281053
[TBL] [Abstract][Full Text] [Related]
6. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
[TBL] [Abstract][Full Text] [Related]
7. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
8. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
[TBL] [Abstract][Full Text] [Related]
9. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene: a review of its use in postmenopausal osteoporosis.
Clemett D; Spencer CM
Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
[TBL] [Abstract][Full Text] [Related]
11. The rise of raloxifene and the fall of invasive breast cancer.
Jordan VC
J Natl Cancer Inst; 2008 Jun; 100(12):831-3. PubMed ID: 18544739
[No Abstract] [Full Text] [Related]
12. Raloxifene: a review of its use in the prevention of invasive breast cancer.
Moen MD; Keating GM
Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
[TBL] [Abstract][Full Text] [Related]
13. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
[TBL] [Abstract][Full Text] [Related]
15. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
Dunn BK; Ford LG
Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
17. Design and methods of the Raloxifene Use for The Heart (RUTH) study.
Mosca L; Barrett-Connor E; Wenger NK; Collins P; Grady D; Kornitzer M; Moscarelli E; Paul S; Wright TJ; Helterbrand JD; Anderson PW
Am J Cardiol; 2001 Aug; 88(4):392-5. PubMed ID: 11545760
[TBL] [Abstract][Full Text] [Related]
18. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Barrett-Connor E; Mosca L; Collins P; Geiger MJ; Grady D; Kornitzer M; McNabb MA; Wenger NK;
N Engl J Med; 2006 Jul; 355(2):125-37. PubMed ID: 16837676
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
20. Serum estradiol level and risk of breast cancer during treatment with raloxifene.
Cummings SR; Duong T; Kenyon E; Cauley JA; Whitehead M; Krueger KA;
JAMA; 2002 Jan; 287(2):216-20. PubMed ID: 11779264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
